This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In the September issue of Pharmaceutical Executive, Lev Gerlovin addresses four main questions that US drugmakers must answer to cope with the evolving payer landscape given rising drug prices. To read the article, click the link below.
This report identifies two key policy objectives that can be generated from healthcare and pharmaceutical spending.
Key takeaways Men with prostate cancer are more likely to die from heart disease, not cancer. Patients who start androgen deprivation therapy (ADT) are...
CRA is a proud sponsor of the summit. Simon Chisholm is a speaker during the session titled “Understanding Lessons and Takeaways from Market Investigations”...
CRA is a proud sponsor of the conference dedicated to providing invaluable opportunities for networking and collaboration with the chance to meet, engage with...
